Please assess the completion status of the following clinical trial:

Trial Title: A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential~* Body mass index (BMI) 18 to 32 kg/m2, inclusive~* In good health, determined by no clinically significant findings from medical history, physical examination. 12-lead ECG, and vital signs~* Clinical laboratory evaluations, complete blood count and urinalysis within the normal range for the test laboratory, unless not deemed clinically significant by the investigator~* Negative test for drugs of abuse at screening and check-in (including alcohol)~* Negative for hepatitis B, hepatitis C and HIV infection~* Non-childbearing potential is defined as: non-pregnant, non-lactating, and either postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy and/or hysterectomy)~Exclusion Criteria:~* Significant history or clinical evidence of any metabolic (including type 1 or 2 diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, GI (including gastric or duodenal ulcers), Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or psychiatric disorder~* History of inflammatory arthritis~* History of symptomatic hypotension~* History of seizure disorders~* History of bipolar or major depressive disorder~* History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be allowed)~* History of alcoholism or drug addiction within 1 year prior to check-in~* Use of any tobacco- or nicotine-containing products within 6 months prior to check-in~* Participation in any other investigational study drug or biological agent trial in which receipt of investigational study drug occurred within 5 half-lives or 30 days, whichever is longer, prior to check-in~* Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in~* History of chronic PPI use (\> 30 days of continuous daily dosing) within 6 months of check-in

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- A: Vismodegib (Type: ACTIVE_COMPARATOR): None
- B: Rabeprazole + Vismodegib (Type: EXPERIMENTAL): None
- C: Itraconazole + Vismodegib (Type: EXPERIMENTAL): None
- D: Fluconazole + Vismodegib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).